2024
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).
Kalinsky K, Barlow W, Pathak H, Gralow J, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Rastogi P, Schott A, Shak S, Tripathy D, Hortobagyi G, Meric-Bernstam F, Sharma P, Pusztai L, Thompson A, Godwin A. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). Journal Of Clinical Oncology 2024, 42: 505-505. DOI: 10.1200/jco.2024.42.16_suppl.505.Peer-Reviewed Original ResearchInvasive disease-free survivalAnti-Mullerian hormoneFollicular stimulating hormoneAnti-Mullerian hormone levelsPremenopausal patientsRecurrence scoreChemotherapy benefitLuteinizing hormoneHormone levelsInhibin BBreast cancerBenefit of endocrine therapyNode-positive breast cancerPhase 3 randomized trialFluorescent bead-based immunoassayDisease-free survivalInvasive breast cancerNormal ovarian reserveSelf-reported menopausal statusSerum anti-Mullerian hormoneBaseline serum samplesSelection of patientsSerum hormone levelsBaseline hormone levelsUniversity of Kansas Medical Center
2015
Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database
Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, Lannin DR. Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database. Journal Of The American College Of Surgeons 2015, 220: 1063-1069. PMID: 25868410, DOI: 10.1016/j.jamcollsurg.2015.02.011.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseNeoadjuvant chemotherapyBreast preservationBreast conservationTumor sizeCancer DatabaseDefinitive breast surgerySmall institutional seriesBreast cancer increasesAdvanced nodal diseaseInvasive breast cancerYounger patient ageBreast tumor sizeLarger tumor sizeMultivariate logistic regressionHigh tumor gradeAmerican Cancer SocietyAdjuvant chemotherapyNodal diseasePrimary surgeryT4 tumorsInstitutional seriesPatient ageRetrospective reviewDistant metastasis
2013
Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer
Abu-Khalaf M, Pusztai L. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer. The Breast 2013, 22: s83-s87. PMID: 24074799, DOI: 10.1016/j.breast.2013.07.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAntineoplastic Agents, HormonalBiopsy, NeedleBreast NeoplasmsChemotherapy, AdjuvantCost SavingsCost-Benefit AnalysisFemaleForecastingGenetic TestingGenomicsHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisReceptors, EstrogenRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsLow-risk patientsBreast cancerRisk patientsTreatment recommendationsEarly-stage breast cancerER-positive breast cancerUse of chemotherapyInvasive breast cancerGenomic testingStage breast cancerInternational practice guidelinesMultivariate prognostic modelCost-effectiveness studiesPotential clinical valueAdjuvant treatmentBreast cancer biomarkersCurrent guidelinesPractice guidelinesClinical utilityClinical valueTumor markersStage IPrognostic modelPrognostic testClinical use
2011
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial
Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Research And Treatment 2011, 128: 783-794. PMID: 21655990, DOI: 10.1007/s10549-011-1612-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCyclic Nucleotide Phosphodiesterases, Type 3FemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansHypoglycemic AgentsInsulinKi-67 AntigenMetforminMiddle AgedReproducibility of ResultsSignal TransductionTumor Suppressor Protein p53ConceptsTumor necrosis factor receptor 1Breast cancerCore biopsyPilot cohortOperable invasive breast cancerNon-diabetic womenOperable breast cancerInvasive breast cancerPrimary breast cancerEffect of metforminNecrosis factor receptor 1Serum insulin determinationsMessenger RNA expressionAnti-proliferative effectsFactor receptor 1Ingenuity Pathway AnalysisDiabetic womenMetformin 500Neoadjuvant chemotherapyControl patientsGastrointestinal upsetMetformin armSerum insulinTherapeutic trialsMetformin treatmentA Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, Hortobagyi GN, Symmans WF. A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. JAMA 2011, 305: 1873-1881. PMID: 21558518, PMCID: PMC5638042, DOI: 10.1001/jama.2011.593.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlgorithmsAnthracyclinesAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleBreast NeoplasmsBridged-Ring CompoundsDisease-Free SurvivalDrug Resistance, NeoplasmFemaleForecastingGene Expression ProfilingGenes, erbB-2Genes, NeoplasmGenomicsHumansMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalOligonucleotide Array Sequence AnalysisPredictive Value of TestsPrognosisProspective StudiesReceptors, EstrogenRiskTaxoidsConceptsDistant relapse-free survivalInvasive breast cancerBreast cancerGenomic predictorsD. Anderson Cancer CenterAnthracycline-based regimensER-negative subsetExcellent pathologic responseProspective multicenter studyRelapse-free survivalAbsolute risk reductionStandard cancer treatmentPredictors of responseIndependent validation cohortAnderson Cancer CenterNegative breast cancerCancer treatment strategiesSequential taxaneNeoadjuvant chemotherapyPreoperative chemotherapyPathologic responseWorse survivalEndocrine sensitivityER statusMulticenter study
2010
Higher parity and shorter breastfeeding duration
Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, Hortobagyi GN, Pusztai L, Symmans WF. Higher parity and shorter breastfeeding duration. Cancer 2010, 116: 4933-4943. PMID: 20665494, DOI: 10.1002/cncr.25443.Peer-Reviewed Original ResearchConceptsTriple-negative BCInvasive breast cancerDuration of breastfeedingBreast cancer phenotypeHigher parityOdds ratioBreast cancerTriple-negative breast cancer (TNBC) phenotypeConsecutive case seriesMultivariate logistic regressionConfidence intervalsAfrican American ethnicityCancer phenotypeShort durationCase seriesFamily historyNegative BCProgenitor cell populationsYounger ageLogistic regressionBreastfeedingAmerican ethnicityDemographic informationCell populationsAge
2009
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine. The Oncologist 2009, 14: 320-368. PMID: 19346299, DOI: 10.1634/theoncologist.2008-0230.Peer-Reviewed Original ResearchMeSH KeywordsAnthracyclinesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorBreast NeoplasmsEverolimusEvidence-Based MedicineFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryIn Situ HybridizationLapatinibNeoplasm StagingPolymerase Chain ReactionPractice Guidelines as TopicPrognosisPyrazolesPyrimidinesQuinazolinesReceptor, ErbB-2RNA, MessengerSirolimusSurvival AnalysisTaxoidsTrastuzumabTreatment OutcomeUp-RegulationConceptsBreast cancerOverall survivalInsulin-like growth factor receptor pathwayClinical Oncology-CollegeMetastatic breast cancerInvasive breast cancerAmerican Pathologists guidelinesHER-2 receptorTyrosine kinase inhibitorsTarget of therapyGrowth factor receptor pathwayKinase inhibitor lapatinibMean relative riskReal-time polymerase chain reactionTransmembrane tyrosine kinase receptorPrediction of responseChromosome 17 polysomyHormonal therapyTyrosine kinase receptorsTherapy toxicitySitu hybridizationPrognostic significancePolymerase chain reactionPathologists guidelinesRelative risk
2007
Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer
Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. British Journal Of Surgery 2007, 95: 433-437. PMID: 18161887, DOI: 10.1002/bjs.6044.Peer-Reviewed Original ResearchConceptsResidual tumour cellularityNeoadjuvant chemotherapyBreast-conserving surgeryResidual cellularityBreast cancerTumor cellularityIntraoperative marginsInitial breast-conserving surgeryResidual invasive breast cancerInvasive breast cancerPrimary tumor areaInvasive lobular carcinomaFalse-negative marginsCent of specimensInvasive tumor cellsLobular carcinomaMargin rateChemotherapyPatientsPathology slidesCellularityTumor areaSurgeryTumor cellsCancerResidual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome
Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L. Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome. Journal Of Clinical Oncology 2007, 25: 2650-2655. PMID: 17602071, DOI: 10.1200/jco.2006.08.2271.Peer-Reviewed Original ResearchConceptsResidual invasive cancerResidual ductal carcinomaDisease-free survivalInvasive cancerResidual DCISDFS ratesNeoadjuvant chemotherapyOverall survivalComplete eradicationOS ratesDuctal carcinomaLocoregional recurrence-free survival ratesLocal recurrence-free survivalRecurrence-free survival ratesTexas M.D. Anderson Cancer CenterM.D. Anderson Cancer CenterOutcomes of patientsRate of patientsInvasive breast cancerLocal recurrence rateRecurrence-free survivalBreast cancer patientsInclusion of patientsAnderson Cancer CenterLong-term survivalDifferential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer
Liedtke C, Mazouni C, Hess K, Tordai A, André F, Symmans W, Gonzalez-Angulo A, Green M, Hortobagyi G, Pusztai L. Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer. Journal Of Clinical Oncology 2007, 25: 10519-10519. DOI: 10.1200/jco.2007.25.18_suppl.10519.Peer-Reviewed Original ResearchTriple-negative statusHigh nuclear gradeTriple-negative breast cancerTriple-negative tumorsLong-term survivalBreast cancerNuclear gradeNeoadjuvant chemotherapyOverall survivalNegative tumorsIndependent unfavorable prognostic factorHER2/neu expressionMD Anderson Cancer CenterComplete pathological responseProgesterone receptor expressionInvasive breast cancerPositive nodal statusTriple-negative groupUnfavorable prognostic factorAnderson Cancer CenterBasal-like subtypeRetrospective comparative analysisNegative control groupNeoadjuvant trialsRemainder patientsEffect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy
Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo A, Symmans F, Meric-Bernstam F, Valero V, Hortobagyi G, Pusztai L. Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy. Journal Of Clinical Oncology 2007, 25: 530-530. DOI: 10.1200/jco.2007.25.18_suppl.530.Peer-Reviewed Original ResearchResidual invasive cancerInvasive cancerResidual DCISSurvival rateNeoadjuvant chemotherapyComplete eradicationDisease-free survival ratesLocal recurrence-free survivalRecurrence-free survival ratesUT MD Anderson Cancer CenterMD Anderson Cancer CenterResidual ductal carcinomaOutcomes of patientsPathologic complete responseRate of patientsInvasive breast cancerLocal recurrence rateOverall survival rateRecurrence-free survivalBreast cancer patientsAnderson Cancer CenterInclusion of casesPatients 78Residual invasivePreoperative chemotherapyBreast Cancer
Ross J, Linette G, Stec J, Clark E, Ayers M, Symmans F, Hortobagyi G, Pusztai L. Breast Cancer. 2007, 269-278. DOI: 10.1007/978-0-387-33227-7_24.Peer-Reviewed Original ResearchBreast cancerInvasive breast cancerCurrent incidence ratesAmerican womenGenetic predisposition testingMicrometastasis detectionSitu diseaseClinical managementIncidence rateField of pharmacogenomicsRNA expression profilingNew casesPredisposition testingCancerMolecular pathologyBiomarker assaysSerum diagnosticsDiseaseWomenExpression profilingFuture assaysAssaysPathology
2006
Is histology (His) relevant in adjuvant (Adj)/neoadjuvant (NA) therapy of breast cancer (BC)?
Katz A, Saad E, Pusztai L. Is histology (His) relevant in adjuvant (Adj)/neoadjuvant (NA) therapy of breast cancer (BC)? Journal Of Clinical Oncology 2006, 24: 10541-10541. DOI: 10.1200/jco.2006.24.18_suppl.10541.Peer-Reviewed Original ResearchInvasive lobular carcinomaHormone therapyILC patientsRandomized trialsInvasive ductal carcinomaNA chemotherapyBreast cancerNA therapyPCR rateRetrospective seriesEstrogen receptorPhase III randomized trialsPathologic response rateRole of chemotherapyIndependent predictive factorsOngoing randomized trialsEarly breast cancerFuture randomized trialsInvasive breast cancerDistinct clinical behaviorPotential therapeutic implicationsAdjuvant trialsCT regimensPossible overtreatmentIDC patients
2005
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding
Symmans W, Fiterman D, Anderson S, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross J, Wagner P, Theriault R, Arun B, Kuerer H, Hess K, Zhang W, Hortobagyi G, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocrine Related Cancer 2005, 12: 1059-1069. PMID: 16322343, DOI: 10.1677/erc.1.01051.Peer-Reviewed Original ResearchConceptsReal-time reverse transcription-polymerase chain reactionInvasive breast cancerImmature cell typesBreast cancerPrimary invasive breast cancerHigh-grade breast cancerMultivariate linear regression analysisReverse transcription-polymerase chain reactionCell typesTranscription-polymerase chain reactionShorter lifetime durationGene expressionParous womenClinicopathologic characteristicsEstrogen receptorHispanic ethnicitySeparate cohortHispanic womenElevated gene expressionLinear regression analysisLifetime historyYounger ageNeu receptorCancerBreastfeedingWeekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks
Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks. Journal Of Clinical Oncology 2005, 23: 5983-5992. PMID: 16087943, DOI: 10.1200/jco.2005.06.232.Peer-Reviewed Original ResearchConceptsPrimary systemic chemotherapyWeekly paclitaxelLymph nodesBreast cancerClinical responseFrequent administrationPathologic complete response rateClinical N0 diseaseDoxorubicin/cyclophosphamidePathologic complete remissionSchedule of paclitaxelClinical stage IComplete response rateIIIA breast cancerOperable breast cancerBreast conservation ratesLymph node involvementInvasive breast cancerLymph node statusDoses of paclitaxelFine-needle aspirationN0 diseaseComplete remissionNode involvementSystemic chemotherapy
2003
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clinical Cancer Research 2003, 9: 5652-9. PMID: 14654548.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCell Cycle ProteinsCOP9 Signalosome ComplexCyclin-Dependent Kinase Inhibitor p27DNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsLymphatic MetastasisMiddle AgedPeptide HydrolasesReceptor, ErbB-2Receptors, EstrogenSurvival AnalysisTime FactorsTranscription FactorsTumor Suppressor ProteinsConceptsNode-negative breast cancerAdjacent normal tissuesInvasive breast carcinomaBreast cancerJab1 overexpressionNormal tissuesBreast carcinomaAdjuvant systemic therapyDisease-free survivalIndependent prognostic factorInvasive breast cancerLow nuclear gradeBreast cancer tissuesExpression levelsProtein-1 expressionBreast tumor tissuesWestern blot analysisDomain-binding protein 1Patient agePrognostic factorsSystemic therapyPrognostic significanceTumor sizeNuclear gradeInvasive tumors
2001
Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry
Esteva F, Hortobagyi G, Sahin A, Smith T, Chin D, Liang S, Pusztai L, Buzdar A, Bacus S. Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry. Pathology & Oncology Research 2001, 7: 171-177. PMID: 11692142, DOI: 10.1007/bf03032345.Peer-Reviewed Original ResearchConceptsPrimary breast cancerBreast cancerHER-2Mitogen-activated protein kinaseQuantitative immunohistochemistryHER-4Frequency of expressionGrowth factor receptorHER-3Early-stage breast cancerFactor receptorHormone receptor statusInvasive breast cancerErbB/Breast cancer tissuesExpression of EGFRYears of ageEvidence of associationReceptor statusLymph nodesTumor sizeHER familyTumor markersTumor specimensCancer tissues